Compare Capri Holdings Ltd (CPRI) vs Cassava Sciences Inc (FLNA) Price & Performance

CPRI trades at $14.95, up 3.53% today, with a bullish technical signal from moving averages and recent positive earnings beats. The stock shows a low P/S of 0.51 and strong gross margins above 62%, but faces challenges with a net loss of $1.18 billion in 2025 and declining revenue trends. Recent news highlights management's focus on brand revitalization and second-half growth expectations for Michael Kors and Jimmy Choo.

The outlook is mixed: valuation appears attractive and earnings momentum is positive, but sustained revenue growth and margin recovery are critical for upside. Key risks include execution on the Michael Kors turnaround, competitive pressures, and macroeconomic sensitivity. The consensus price target of $20.57 suggests potential appreciation if operational improvements materialize.

FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.

While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.